Unknown

Dataset Information

0

Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.


ABSTRACT: Purpose:This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods:We retrospectively reviewed the medical records of 199 chemotherapy-naïve patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results:The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score ?8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125-0.958). Conclusions:Enzalutamide is effective and safe for chemotherapy-naïve patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.

SUBMITTER: Jung SI 

PROVIDER: S-EPMC6946821 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.

Jung Seung Il SI   Kim Myung Soo MS   Jeong Chang Wook CW   Kwak Cheol C   Hong Sung Kyu SK   Kang Seok Ho SH   Joung Jae Young JY   Lee Seung Hwan SH   Yun Seok Joong SJ   Kim Tae-Hwan TH   Park Sung Woo SW   Jeon Seong Soo SS   Kang Minyong M   Lee Ji Youl JY   Chung Byung Ha BH   Hong Jun Hyuk JH   Ahn Hanjong H   Kim Choung-Soo CS   Kwon Dong Deuk DD  

Investigative and clinical urology 20191210 1


<h4>Purpose</h4>This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients.<h4>Materials and methods</h4>We retrospectively reviewed the medical records of 199 chemotherapy-naïve patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (A  ...[more]

Similar Datasets

| S-EPMC9123068 | biostudies-literature
| S-EPMC4869571 | biostudies-literature
| S-EPMC8326386 | biostudies-literature
| S-EPMC9385484 | biostudies-literature
| S-EPMC8616757 | biostudies-literature
| S-EPMC10107622 | biostudies-literature
| S-EPMC5570461 | biostudies-literature
| S-EPMC7467473 | biostudies-literature
| S-EPMC4524760 | biostudies-other
| S-EPMC7604981 | biostudies-literature